ARTICLE | Financial News

Evolus prices $60M IPO

February 9, 2018 4:24 PM UTC

Medical aesthetics company Evolus Inc. (NASDAQ:EOLS) raised $60 million on Feb. 8 through the sale of 5 million shares at $12 in an IPO underwritten by Cantor Fitzgerald, Mizuho, SunTrust Robinson Humphrey and JMP Securities. The price was at the low point of Evolus' proposed $12-$14 range, and valued the company at $283.1 million.

Evolus is developing prabotulinumtoxinA (DWP-450), an injectable 900 kilodalton (kDa) botulinum toxin type A complex, to treat adults with glabellar lines (frown lines between the eyebrows). The therapy, which met the primary endpoints in three Phase III trials, is under FDA and EMA review...

BCIQ Company Profiles

Evolus Inc.